162 related articles for article (PubMed ID: 29407765)
1. Role of membrane cholesterol in differential sensitivity of muscarinic receptor subtypes to persistently bound xanomeline.
Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
Neuropharmacology; 2018 May; 133():129-144. PubMed ID: 29407765
[TBL] [Abstract][Full Text] [Related]
2. Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.
Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
Pharmacol Res; 2015 Jul; 97():27-39. PubMed ID: 25882246
[TBL] [Abstract][Full Text] [Related]
3. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
Grant MK; El-Fakahany EE
J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
[TBL] [Abstract][Full Text] [Related]
4. Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.
Šantrůčková E; Doležal V; El-Fakahany EE; Jakubík J
PLoS One; 2014; 9(2):e88910. PubMed ID: 24558448
[TBL] [Abstract][Full Text] [Related]
5. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2004 Jan; 308(1):105-10. PubMed ID: 14569060
[TBL] [Abstract][Full Text] [Related]
6. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2002 Jun; 301(3):1033-41. PubMed ID: 12023535
[TBL] [Abstract][Full Text] [Related]
7. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
9. Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor.
Noetzel MJ; Grant MK; El-Fakahany EE
Neurochem Res; 2009 Jun; 34(6):1138-49. PubMed ID: 19082883
[TBL] [Abstract][Full Text] [Related]
10. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
Machová E; Jakubík J; El-Fakahany EE; Dolezal V
J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
[TBL] [Abstract][Full Text] [Related]
11. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
13. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
[TBL] [Abstract][Full Text] [Related]
14. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
[TBL] [Abstract][Full Text] [Related]
15. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.
Grant MK; Noetzel MJ; De Lorme KC; Jakubík J; Doležal V; El-Fakahany EE
PLoS One; 2010 Dec; 5(12):e15722. PubMed ID: 21203415
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding.
Noetzel MJ; Grant MK; El-Fakahany EE
Pharmacology; 2009; 83(5):301-17. PubMed ID: 19401618
[TBL] [Abstract][Full Text] [Related]
18. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
20. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
Martino G; Puma C; Yu XH; Gilbert AK; Coupal M; Markoglou N; McIntosh FS; Perkins MN; Laird JMA
Pain; 2011 Dec; 152(12):2852-2860. PubMed ID: 22018972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
